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Chapter 1 
 
 
 
 
 
Introduction 
 
a. Purpose of the study 
Cancer is a disease that affects the lives of millions worldwide as no cure exists. According 
to the American Cancer Society, it was projected that in 2010 alone, there would be a total of 
1,529,560 new cases of cancer and 569,490 deaths from cancer.1 Of these new cases, nearly 
36,540 of them will be caused from squamous cell carcinoma of the oral cavity and pharynx, 
causing about 8,000 deaths.1 Although no cure for cancer is currently available, there is a 
strong connection between survival rate and early detection. According to a 2008 study on 
lung cancer, it was found that 84% of cases are diagnosed at an advanced stage.2 In the same 
year, 1.5 million people worldwide were diagnosed, leaving 1.3 million people dead.2 
Patients diagnosed at an early stage, however, have an 86% overall five-year survival.2 For 
this reason, early detection strategies must be employed if mortality rates are to decrease.  
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The goal of this research is to develop an extremely sensitive and accurate method for early 
detection cancer biomarker proteins and monitoring response to therapy. Ideally, the method 
will lead to reduced costs of treatment, stress among patients and families, and provide 
devices for early screening and on-the-spot diagnosis. Interleukin-8 is a cytokine involved in 
the inflammatory response.3 When found at elevated concentrations in the human blood 
serum, IL-8 serves as a biomarker for many cancers, including head and neck squamous cell 
carcinoma (HNSCC). HNSCC poses an extreme difficulty in monitoring a biomarker for 
early detection, thus leading to diagnoses at advanced stages.4  
This pell honors senior thesis (chapter 2) demonstrates recent advances in 
electrochemical detection of cancer biomarker IL-8 in a clinically relevant calf serum 
sample. Two immunosensor approaches were employed, resulting in a detection range of 1.0 
fg mL-1 to 2000 pg mL-1. The approach taken used nanostructured electrodes with a 
glutathione protected gold nanoparticle (GSH-AuNP) platform along with 1.0 µm 
superparamagnetic beads. Antibody-antigen chemistry was used on the electrode along with 
the beads for an ulatrsensitive immunoassay. The beads bound horseradish peroxidase (HRP) 
to react with injected hydrogen peroxide (H2O2). The change in current that results from this 
reaction correlates to the concentration of IL-8 antigen present, creating the calibration curve 
and detection range.  
The initial studies involved optimization of the concentrations of the capture (Ab1) and 
detection (Ab2) antibodies in the sandwich immunosensor protocol. This critically important 
step in immnosensor development minimizes non-specific binding events (NSB) that often 
control the detection limits.  The optimum analytical conditions for IL-8 detection was were 
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then used to produce the calibration curves, giving us the detection range. Our most sensitive 
method  usinf massively labeled 1 mm superparamagnetic beads gaive an IL-8 detection limit 
of 1 fg mL-1 which is 30,000 fold lower detection limit than the current ELISA method used 
in hospitals.  
Chapter 3 addresses the economic and political implications of early detection of cancer. 
The importance of the cancer research being conducted in the laboratory is that it will be 
implemented into the lives of those infected with cancer. The lines of communication are a 
key aspect to making the hands-on research worthwhile. The information and conclusions 
reached must get into the hands of policymakers and doctors in order to make early detection 
in hospitals possible. This chapter takes a look at the importance of communication and what 
is being done about it currently. It also integrates the current costs of treating head and neck 
cancer versus treating a case of cancer that has been detected early.  
Finally, chapter 4 discusses improvements that can be made for cancer. Education and 
advocacy are crucial components in improving cancer rates and statistics. In order for one to 
accurately know the health factors that can increase or decrease cancer risks, education is 
vital. Examples of educated versus non-educated smokers are compared, along with 
examples of improvements made from advocacy. The chapter moves forward to look at what 
is needed in legislation to implement needed laws. The final stage of this chapter focuses on 
the idea of an “aging society” and how it will affect the future of cancer research and early 
detection.  
b. Interleukin 8 
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Interleukin 8 is a cytokine that is released by monocytes and other cell types as a response to 
an inflammatory stimulus.5 Specifically, IL-8 activates leukocytes, which have a role as 
novel mediators of inflammation. IL-8 was originally found in cultures of human blood 
monocytes, and it was later found to be biologically active in tumor cells.6 Interleukin 8 has 
been found to be correlated with the presence of head and neck squamous cell carcinoma.7 
The three dimensional structure of interleukin 8 derived from the Brookhaven Protein Data 
Bank is shown in Figure 1.8 
 
 
 
 
 
 
 
 
 
 
 
8 
 
 
Figure 1: Three dimensional structure of interleukin 8 in solution according to the 
Brookhaven Protein Data Bank.  
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c. GSH-AuNP platform 
Our immnunosensor protocol utilizes glutathione protected gold nanoparticles (GSH- AuNP) 
assembled on a pyrolytic graphite (PG) electrode. The GSH-AuNP were synthesized using a 
mixture of Methanol, HAuCl4, glutathione, NaBH4 and HEPES buffer following an 
established procedure. Poly(diallyldimethylammonium chloride) (PDDA) is a positively 
charged organic molecule, while GSH-AuNP are negatively charged. Because of the opposite 
charges, the GSH-AuNP can be adsorbed onto the monolayer of PDDA (3). This is done by 
adding 20 mL of 3mg/mL PDDA solution containing 0.5 M NaCl for 20 min. The electrode 
is then placed with 10 mL of 130 mM GSH-AuNP for 20 minutes. This causes an 
electrostatic force between the PDDA and GSH-AuNP and creates the platform in which the 
capture antibody can bind.  
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Figure 2: Atomic force microscopy image of GSH-AuNP platform atop the PG electrode. This 
picture demonstrates even distribution along the electrode tip of nanoparticles approximately 5 
nm in size.  
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Chapter 2 
 
 
 
 
 
 
 
Electrochemical Detection of IL-8 Biomarker Using 
Nanotechnology 
 
 
 
 
 
a. Abstract 
Herein we report on an ultrasensitive immunosensor based on glutathione protected gold 
nanoparticle (GSH-AuNP) for the electrochemical detection of interleukin 8 (IL-8), cancer 
biomarker in calf serum and proof of concept IL-8 detection in HNSCC cells. GSH-AuNP 
were bioconjugated to the primary antibodies (Ab1) and used to capture human IL-8 in a 
sandwich electrochemical immunoassay coupled to horseradish peroxidase enzyme labels. 
Using the optimized concentrations of the primary (Ab1) and secondary antibodies (Ab2), two 
sensor approaches were used to measure ultra low (≤ 500 fg mL-1) and elevated levels of IL-
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8. Biotinylated Ab2 bound to streptavidin HRP with 14-16 labels per antigen was used to 
measure high IL-8 concentration with a DL of 10 pg mL-1 (1.0 pM) in 10 µL calf serum. The 
second approach greatly amplified the signal using 1 µm magnetic beads coated with over 
500,000 HRP labels providing the highest sensitivity of (1061.8 nA mL (fg IL-8)-1 cm-2 and 
the best detection limit of 1 fg mL-1 (100 aM) for IL-8 in 10 µL calf serum.  This represents a 
10,000-fold and 30,000-fold decrease in the DL over the Ab-HRP(14-16) system and the 
industry standard ELISA for IL-8 respectively.  The immuonsensors were also used to 
accurately measure IL-8 in HNSCC cell lines with excellent correlation to the standard 
enzyme linked immunosorbent assay (ELISA). These GSH-AuNP based immuonsensors 
show great promise for the fabrication of ultrasensitive biosensor microarrays for point-of-
care cancer diagnosis.   
b. Introduction 
The measurement of biomarker proteins for early detection and monitoring of cancer 
poses an incredible challenge. However, the development of an extremely sensitive and 
accurate system that requires only simple maintenance is critically important and will lead to 
reduced costs of treatment, stress among patients and families, and will provide devices for 
early cancer screening and on-the-spot diagnosis.1,2,3 Such devices will also offer a 
fundamental understanding of disease progression and allow monitoring of patients response 
to therapy.4 
Interleukin-8 (IL-8) is a cytokine involved in the inflammatory response. It is a biomarker 
protein found at elevated levels in the presence of many different types of cancers including 
head and neck squamous cell carcinoma (HNSCC).5,6,7,8,9  Approximately, 37,000 patients are 
diagnosed with HNSCC each year in the United States and about 8,000 results in death.10 
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This high number of deaths is due to the difficulty in monitoring a measurable biomarker 
protein for early detection, usually resulting in diagnosis at advanced stages.10 The average 
concentration of IL-8 found in a healthy individual is ≤ 13 pg mL-1, compared to the elevated 
levels of ≥ 20 pg mL-1 in patients with HNSCC.11 In order to give a reliable diagnosis and 
accurately monitor the HNSCC, changes in both normal and elevated levels of IL-8 need to 
be measured.  
A single biomarker found at an elevated level, however, does not give complete accuracy 
for a diagnosis. For example, PSA, the most widely used serum biomarker for prostate 
cancer, has a positive predictive value of ~75%.12 Recent studies have shown that ~100% 
predictive success can be achieved by measuring 5 to 10 biomarkers of a particular 
cancer.13,14,15,16 Multi-protein arrays are necessary for point-of-care detection. The 
ultrasensitive immunosensor development for IL-8 serves as the starting point to the 
development of electrochemical immunosensor arrays for many different biomarker proteins.  
Conventional immunoassay methods, including enzyme-linked immunosorbent assay 
(ELISA),17,18 fluorescence immunoassay, 19,20 surface Plasmon resonance (SPR),21,22 
magnetic bead-based electrochemilumincence(ECL),23 chemiluminescence,24,25,26 liquid 
chromatograpy-mass spectrometry (LC-MS)27,28,29 and immuno-polymerase chain reaction 
(PCR) assay30 allow reliable protein detection. However, these approaches are yet to meet all 
requirements for point-of-care diagnosis which require the sensor to be rapid, operationally 
simple, low cost and highly sensitive to address both levels of the biomarkers in normal and 
cancer patient serum. Recent methods for sensitive protein detection including nanowire 
nanotransistor,31 arrays based on electrochemical32,33 and optical34 detection have been 
15 
 
reported. These methods are however at an early stage of development and have not been 
applied to measure IL-8 in real samples.  
Our group is focused on using nanostructured electrodes coupled to multi-label signal 
amplification strategies to achieve highly sensitive electrochemical immunosensors. 
Previously, we have reported on a non amplified AuNP immunosensor for the detection of 
IL-6 with a DL of 10 pg mL-1 in calf serum.35 More recently, we reported a DL of 0.5 pg mL-
1
 for PSA in serum using ~1 µm magnetic beads containing ~7500 HRPs per nanoparticle.36    
Alternatively, we have used vertically aligned SWNT immunosensors coupled to multi-
labeled HRP-multiwall carbon nanotubes (MWNT)-HRP-Ab2 bioconjugate to obtain a DL of 
0.5 pg mL-1 for IL-637 and 4 pg mL-1 for PSA38 in serum respectively. In another strategy we 
used 0.5 µm multi-labeled polymeric beads, polybeads–HRP-Ab2 to achieve a DL of 10 pg 
mL-1 for MMP-339 in calf serum.  
Herein, we report on an electrochemical immunosensor for detection of both very low 
and elevated levels of IL-8. The highly sensitive immunosensor is achieved by the use of ~5 
nm glutathione gold nanoparticle (GSH-AuNP) platform, coupled with ~1.0 µm magnetic 
beads conjugated to the detection IL-8 antibody (Ab2) and hundreds of thousands of 
horseradish peroxidase enzyme (HRP) labels (Ab2-MB-HRP) via avidin-biotin interaction.  
This approach provides the highest number of HRP labels per binding event allowing 
extremely sensitive monitoring of any changes in serum concentration. The immunosensor is 
assembled on an electrode with a pyrolytic graphite tip, starting with the platform of GSH-
AuNP. The capture antibody (Ab1) is bound to the platform, followed by the IL-8 antigen. 
The magnetic bead conjugate is added to bind Ab2 to the antigen. The signal produced 
through amperometry is proportional to the concentration of IL-8 antigen. At high IL-8 levels 
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we used Ab2 conjugate with 14-16 labels per antigen providing a DL of 10 pg mL-1 in serum 
while for ultrahigh sensitivity, the multi-labeled Ab2-MB-HRP bioconjugate method gave a 
remarkable detection limit of 1.0 fg mL-1. This DL is 30,000-fold lower than the 
conventional hospital ELISA method. This ultralow DLs show the AuNP immunosensor 
offer great potential for early cancer detection and point-of-care cancer screening. Most 
importantly, the device is amenable to future immunosensor array fabrication. 
c. Experimental Section 
Chemicals and Materials. Monoclonal antihuman interleukin-8 (IL-8) antibody, 
biotinylated antihuman IL-8 antibody, recombinant IL-8 (carrier-free) in calf serum, and 
streptavidin-horseradish peroxidase (HRP) were from R&D Systems, Inc. (Minneapolis, 
MN). Biotinylated HRP was from Invitrogen. HRP (MW 44 000 Da), lyophilized 99% 
bovine serum albumin (BSA), and Tween-20 were from Sigma Aldrich. Methanol, (99% - 
spectrophotometric grade), 99.99% Acetic acid (glacial), 99.99% Sodium borohydride 
(granules), 99.9% Gold (III) chloride trihydrate, and L-Glutathione (reduced) used in the 
synthesis of the glutathione protected gold nanoparticle platform were from Sigma Aldrich. 
Poly(diallyldimethyl ammonium chloride) (PDDA), 20 wt. % in water was also from Sigma 
Aldrich.   Immunoreagents were dissolved in pH 7.2 phosphate saline (PBS) buffer (0.137 M 
NaCl, 2.7 mM KCl, 8.1 mM Na2HPO4, 1.5 mM NaH2PO4). 1-(3-(dimethylamino)-propyl)-3-
ethylcarbodiimidehydrochloride (EDC) and N-hydroxysulfosuccinimide (NHSS) from 
Aldrich were dissolved in water immediately before use. 
Cell Lines and Conditions 
Immunosensor Fabrication. A gold nanoparticle platform was assembled on the pyrolytic 
graphite (PG) tip of an electrode using a monolayer of Poly(diallyldimethyl ammonium 
17 
 
chloride) (PDDA). Glutathione protected gold nanoparticles (GSH-AuNP) were synthesized 
using a reaction mixture containing acetic acid, methanol, and sodium borohydride, followed 
by the addition of gold chloride and glutathione to optimally obtain 5 nm gold particles 
coated with glutathione. The GSH-AuNPs were then adsorbed on the electrode surface by the 
electrostatic layer-by-layer self assembly using PDDA polyion “glue”. Capture antibody 
(Ab1) was attached to the GSH-AuNP platform using 30 µL freshly prepared mixture of 400 
mM EDC and 100 mM NHSS in water, washing after 10 minutes, then incubating overnight, 
for 9 hours, with 20 µL of 10 µg mL-1 primary anti-IL-8-antibody (Ab1) in pH 7.2 PBS 
buffer. Then the immunosensor was washed with 0.05% Tween-20 in PBS buffer for 3 
minutes, replacing with new buffer after 1.5 minutes, and then washed with PBS buffer for 3 
minutes, for a total of 4 washes. A blocking step involved a 1 h incubation with 20 µL of 1% 
BSA, followed by another wash with 0.05% Tween-20 in PBS buffer then with PBS buffer 
for 3 minutes each. Washing steps were optimized in previous experiments to minimize non-
specific binding (NSB) to achieve the optimum sensitivity.39  
For standardization, the immunosensor was incubated with 10 µL of calf serum 
containing human IL-8 for 1 h 15 min, followed by washing with 0.05% Tween-20 in PBS 
buffer and PBS buffer for 3 minutes each. Next, 10 µL of 0.05 µg mL-1 biotinylated detection 
antibody (Ab2) in 1% BSA was incubated for 1 h 15 min, followed by washing with 0.05% 
Tween-20 in PBS buffer and PBS buffer for 3 minutes each. For the amplified system assay, 
the blocking step required an increase to 5% BSA. For moderate sensitivity, the 
immunosensor was incubated with 10 µL of streptavidin-HRP for 30 min, followed by 
washing with 0.05% Tween-20 in PBS buffer and PBS buffer for 3 minutes each. For a more 
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sensitive detection, the Ab2 and HRP incubations were replaced by a multilabel Ab2-
Magnetic Bead-HRP bioconjugate (Ab2-MB-HRP) (described below). 
The sensor was then placed in an electrochemical cell containing 10 mL of pH 7.2 PBS 
buffer with 1 mM hydroquinone as a mediator. Amperometry was used by rotating the disk at 
2000 rpm, and then injecting 0.4 mM H2O2 to generate the electrochemical signal. This same 
immunoassay was used to detect conditioned media from cell cultures previously described.37 
These samples were also analyzed using a standard human IL-8 Elisa kit. 
Synthesis of Ab2-Magnetic Bead-HRP Bioconjugate. Streptavidin coated magnetic beads 
were conjugated to multiple HRP labels and Ab2 in order to detect the small concentration of 
IL-8 antigen. 200 µL (1 mg) of the beads were dispersed in 800 µl of PBS buffer. The 
magnetic beads were washed two more times with 1000 µl of PBS buffer. The washing step 
was done using MCB 1200 Biomagnetic separation platform (Sigris research, CA) while 
stirring at 1.0 rotation per second for 1 minute each. Using the MCB  magnetic platform, the 
beads were separated from the supernatant, which was removed. After the 3 washes, the 
streptavidin modified magnetic beads were dispersed in a 50 µL of PBS buffer containing 1 
mg mL-1 biotinylated HRP and 0.5 µg mL-1 biotinylated Ab2 at a concentration ratio of 
2000:1 respectively. The magnetic beads were incubated while spinning the homogeneous 
mixture at 0.5 rotations per second on the MCB platform for 30 minutes. Then, the magnetic 
beads conjugate (Ab2-MB-HRP) were magnetically separated and the supernatant removed. 
This step was necessary to remove any free HRP and Ab2. This was then followed by a 
quenching step where the beads were dispersed in 1000 µL PBS buffer with 1% BSA, 0.1% 
NaN3 and 1mM Sodium EDTA for 30 minutes at 0.5 rotations per second. The supernatant 
was removed again using the MCB magnetic platform, and the beads were then washed with 
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PBS buffer 3 more times. Finally, the conjugate, Ab2-MB-HRP was dispersed in 200 µL of 
PBS + 0.1%T-20, 5 mg mL-1, stored in the refrigerator at 4oC, and then diluted with PBS + 
0.1% Tween 20 before use. The magnetic beads conjugate were characterized using ABTS 
activity assay. 
d. Results 
Immunosensor Strategy. Scheme 1 show the electrochemical immunosensor steps, 
including a traditional labeled protocol (A) and a signal amplification strategy using 
multienzyme-antibody labels (B) on glutathione modified gold nanoparticles (AuNPs). 
Herein, we used Glutathione modified gold nanoparticles (GSH-AuNP) platform and 
multienzyme labeling strategy to enhance sensitivity and detection limits. AFM image of the 
immunosensor platform (Scheme 1, insert) show ~ 5 nm AuNPs consistent with previous 
reports40 Our initial approach for elevated IL-8 antigen (Scheme 1A), we utilized a sensitive 
Ab2-biotin-streptavidin-HRP (14-16) label for each assay. Minimization of non-specific 
binding (NSB) events is critical to achieving best sensitivity and detection limits.41,42 BSA 
and Tween 20 were used to effectively block NSB. Furthermore, the capture antibody 
(Figure 1A) and detection antibody (Figure 1B) concentrations were optimized. Optimization 
experiments were done using 4.0 ng mL-1 of IL-8 in calf serum with all other components of 
the immunoassay kept constant. Figure 1A(a) shows results of the complete immunoassay 
with fixed detection antibody, Ab2 concentrations at 1 µg ml-1 while varying the capture 
antibody, Ab1 concentration. Control experiments, Figure 1A(b) to assess the level of NSB 
events involved all the immnosensensor steps with serum without the hIL-8 antigen. Results 
gave an optimum Ab1 concentration at 10 µg mL-1 with the lowest signal response for control 
compared to the sample. Similarly, Ab2 concentration was optimized using the best  
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Scheme 1. Illustration of detection principles of AuNP immunosensors. Picture (A) on the left 
shows the immunosensor after treating with a biotinylated Ab2 followed by streptavidin modified 
HRP resulting in HRP-Ab2 providing 14-16 label per binding event. Picture (B) on the right 
shows the immunosensor after treating with Ab2-MB-HRP to obtain amplification by providing 
500,000 enzyme labels per binding event. On the bottom left is a tapping mode atomic force 
microscope image of a AuNP that serves as the immunosensor platform.  
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Figure 1. Optimization of; (A) Capture antibody, Ab1 using [Ab2] at 1 µg mL-1 and (B) detection 
antibody, Ab2 using optimum [Ab1] at 10 µg mL-1. Streptavidin modified HRP label is used to 
generate the electrochemical signal  after dilution at 1:200 ratio. (a) incubation with [hIL-8] at 
4.0 ng mL-1 in new born calf serum for 1 h 15 min and (b) control, indicating full immunoassay 
with serum containing 0 pg mL-1 hIL-8.  
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conditions obtained in Figure 1A. Figure 1B shows the optimum Ab2 concentration at 0.05 
µg mL-1. These optimal analytical conditions for the immunosensor were used to obtain a 
calibration curve with a sensitivity of 0.3395 nA mL (pg IL-8)-1 cm-2 and detection limit for 
the Ab2-HRP(14-16) system of 10 pg mL-1 human IL-8 antigen as shown in Figure 2. Figure 2A 
presents data obtained from the actual amperometric responses of 6 different concentrations 
of IL-8 that range from 10 pg mL-1 to 2000 pg mL-1. The calibration curve (Figure 2B) shows 
there is a linear relationship between the concentration of IL-8 and the change in current as a 
result of the amperometric response. However, a more sensitive system is required in order to 
detect levels of IL-8 that fall below this detection limit.  
The Ab2-Magnetic Bead-HRP conjugate was used to significantly increase the sensitivity 
of our system. This amplified system allowed for ultrahigh sensitivity by greatly increasing 
the amount of HRP labels, which corresponds to the concentration of hIL-8 in a given sample 
through the amperometric response. Our strategy involved bioconjugating biotinylated HRP 
and Ab2 to streptavidin coated magnetic bead with a reaction mixture having a 6800/1 
HRP/Ab2 mole ratio. The mutilabelled magnetic particles with hundred thousands of HRP 
labels were used in place of the conventional Ab2-HRP(14-16) complex.  
Streptavidin-biotin interaction (Ka = 1015/M vs. 107-1011/M for antibody-antigen 
interactions) 43 was used to simultaneously attach the Ab2 and HRP to the 1 µm magnetic 
bead. To determine the amount of active HRP per unit weight of magnetic beads, the Ab2-
MB-HRP dispersion was reacted with HRP substrate 2,2’-azino-bis-(3-ethylbenzthiazoline-6-
sulfonic acid) (ABTS)44 and H2O2. The reaction produces a soluble product with 
characteristic optical absorbance at 405 nm. A linear increase in absorbance of the product at  
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Figure 2. Amperometric response for AuNP immunosensor incubated with hIL-8 in 10µL 
undiluted newborn calf serum for 1.25 h then conventional anti-IL-8-biotin in 0.05% Tween-20 
for 1.25 h followed by 30 min incubation with 10 µL streptavidin modified HRP at 1:200 
dilution, (A) showing current response at -0.3 v and 2000 rpm after placing electrodes in buffer 
containing 1 mM Hydroquinone mediator, then injecting H2O2 to 0.4 mM to develop the signal. 
Control shown on the left, indicating full immunoassay with serum containing 0 pg mL-1 hIL-8. 
(B) Corresponding calibration curve of hIL-8. Errors bars in part B showing device-to-device 
Standard deviations (n = 3). 
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Figure 3. Results of enzyme activity assay of (a) HRP-Magnetic beads-Ab2 bioconjugate and (b) 
control beads without HRP activated by H2O2 with ABTS as substrate to give colored product 
with absorbance at 405 nm. 
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405 nm (Figure 3) was found, and the slope was used to estimate45 an HRP activity of 162.6 
Units mL-1 of undiluted Ab2-MB-HRP. This was compared to a standard curve constructed 
with underivatized HRP, after subtracting the background absorbance of an equivalent 
dispersion of underivatized magnetic beads.  
The concentration of active HRP in the stock Ab2-MB-HRP dispersion was determined in 
this way to be 175.9 µg mL-1.  Considering 1.0 mg  of magnetic beads used to prepare the 
Ab2-MB-HRP conjugate, we had 3.99 µmols HRP/mg beads or 19.98 µmol HRP/mL of 
dispersion. Using the manufacturer’s specifications for the beads with 1 µm diameters and a 
density of 5 x 109 beads/mL, the number of active HRP was estimated at 502,688 per bead.   
In order to reduce NSB in the amplified system, it was necessary to increase our blocking 
step from 1% to 5% BSA with the same amount of incubation time. Calibration data for the 
GSH-AuNP assay utilizing the Ab2-MB-HRP bioconjugate with IL-8 in 10 µL dissolved calf 
serum is presented in Figure 4. In Figure 4A, the increasing change in current, represented by 
the actual amperometric response achieved with the addition of increasing concentrations of 
IL-8, ranges from 1 fg mL-1 to 500 fg mL-1. Figure 4B presents a non-linear calibration curve 
for the amplified system with an extremely low detection limit of 1 fg mL-1. This was 
achieved by using the Ab2-MB-HRP bioconjugate, which significantly increased the 
sensitivity of the system as compared to the Ab2-HRP(14-16) system. Results show that the 
amplified system can detect concentrations of IL-8 10,000-fold lower than that of the Ab2-
HRP(14-16) system.  
IL-8 Secreted by Human Squamous Cells. As a proof of concept we then used the 
immunosensor to determine secreted levels of IL-8 in vitro cell preparations. Conditioned 
media from heterogeneous populations of 7 different cell lines were analyzed to test the  
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Figure 4. Amperometric response for AuNP immunosensor incubated with hIL-8 (concentration 
in fg mL-1, labeled on curves) in 10 µL undiluted newborn calf serum for 1.25 h. (A) Current at -
0.3 V and 2000 rpm using Ab2-magnetic beads –HRP bioconjugate. Control shown on left with 
AuNP immunosensor with 0 pg mL-1 IL-8. (B) The corresponding  calibration curve of hIL-8 
immunosensor using Ab2-Magnetic beads-HRP bioconjugate. Errors bars in part B represent 
device-to-device standard deviations.  
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Figure 5. Amperometric response for AuNP immunosensor incubated with hIL-8 labeled on 
curves or conditioned media containing hIL-8 secreted by human squamous cells. Conditioned 
media samples SF, HaCat, NHOK26, HEp2, HN13, OSCC3 and Cal27 were analyzed using 10 
µL of 0.05 mg mL-1 biotinylated secondary antibody (Ab2) in 0.1 % BSA in pH 7.2 PBS buffer 
and 10 µL of streptavidin modified HRP. (A) Current at -0.3 V and 2000 rpm using 
hydroquinone mediator in PBS buffer, after injecting H2O2 to 0.4 mM; (B) AuNP sensor results 
for conditioned media shown with results from ELISA for the samples. 
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validity of our immunosensor approach towards hIL-8 detection in head and neck squamous 
cell carcinoma (HNSCC). Figure 5A shows amperometric signals for difference cell lines 
along with human hIL-8 standards in serum at comparable levels. Most of the cell lines 
(HEp2, HN13, OSCC3, Cal27) were found to contain high levels of IL-8, ranging from 612 
to 1759 pg mL-1, while HaCat and NHOK26 demonstrated low levels of the antigen , ranging 
from 46 to 99 pg mL-1. Samples were also analyzed using the standard hospital ELISA 
method, and gave excellent correlations with our AuNP immunosensor (Figure 5B). These 
results suggest the validity of using this imunosensor for measurement of hIL-8 levels in 
samples of a variety of cancer cell types. 
e. Discussion 
Results described above show AuNP immunosensor coupled to multilabel amplification 
strategy can be used to accurately and reproducibly detect protein cancer biomarkers at 
extremely low, fentogram  to thousand picograms per milliliter in clinical serum samples 
(Figure 2 & 4) and  complex biological matrix (Figure 5). Two approaches were used to 
achieve such low detection limit including the Ab2-HRP(14-16) and Ab2-MB-HRP with 
502,688 HRP labels providing the best sensitivity of 1061.8 nA mL (fg IL-8)-1 cm-2 at low 
concentrations (1 – 50 fg mL-1) and a remarkable low detection limit of 1.0 fg mL-1 (Figure 
3). The extremely high HRP label loading on the magnetic bead bioconjugate is achieved by 
taking advantage of streptavidin-biotin interactions. This detection limit is 10,000-fold and 
30,000-fold lower than the Ab2 biotin-streptavidin-HRP(14-16) and the standard ELISA46 
techniques respectively. Furthermore, the sensitivity is 6-orders of magnitude better than the 
Ab2-HRP(14-16).  Moreover, these results offer 500-fold lower detection limit and 55000-fold 
better sensitivity than our recent results using SWNT forest immunosensor37 reported for IL-
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6, a cytokine similar to IL-8. This extremely low detection limits were achieved by effective 
minimization of NSB which often controls the detection limits using BSA and tween-20 and 
optimization of the capture and detection antibody concentrations respectively (Figure 1).   
The two AuNP immunosensor approaches, Ab2-HRP(14-16) and Ab2-MB-HRP show good 
reproducibility as demonstrated by small device to device standard deviations (Figures 3, 4-
5). Furthermore, good accuracy for hIL-8 was demonstrated by good correlation of AuNP 
immunosensor results with ELISA assay for a wide variety of conditioned media samples. 
Accurate determination of IL-8 in conditioned media which normally contains a range of 
other proteins demonstrated selectivity of our immunosensor.  
f. Conclusions 
We have demonstrated ultrasensitive, selective and reproducible electrochemical 
detection of IL-8 representative of extremely low, cancer free and high level cancer patients 
in a broad range of head and neck cancer cell lines. The streptavidin modified magnetic bead 
amplification strategy gave extremely high sensitivity of 1061.8 nA mL (fg IL-8)-1 cm-2 and 
ultra-low detection limit of 1.0 fg mL-1 which is 30,000-fold lower than the conventional 
hospital ELISA method. These results show great promise for the fabrication of immosensor 
arrays for point-of-care cancer screening and monitoring of patients response to therapy. 
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Chapter 3 
 
 
 
 
 
 
 
 
Current Ways of Addressing Head/Neck Squamous Cell 
Carcinoma 
 
 
a. Communication 
 
Cancer in general is a disease that almost every family in the world has to overcome at 
some point in time. Increased awareness over the past few decades has shown a more 
accurate number of how many people really suffer from all different kinds of cancer. With 
head and neck squamous cell carcinoma affecting nearly 37,000 people a year,1 awareness is 
absolutely essential. Unfortunately, in most cases, the diagnosis of this disease is delayed 
because it relies on the patient presenting his/her concerns to the doctor and physical 
examination with biopsy confirmation2. Thus, the majority of patients with head and neck 
cancer are not diagnosed until the cancer mass has become life-threatening.3 
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Due to such late diagnoses, the survival rate has not shown appreciable change in 
decades. Five-year survival data reveal overall disease specific survival rates of less than 
60%, although those who do survive often endure major functional, cosmetic, and 
psychological burden due to dysfunction of the ability to speak, swallow, breathe, and chew. 
3 Such devastating statistics has made it very much the will of a huge sector of Americans to 
change the course of cancer. 4 
Easily, the most important aspect of cancer research is the communication between the 
researchers and policymakers. While laboratory workers find promising and successful 
results of early detection, they must get these results into the hands of doctors and nurses 
who can accurately update treatment and early testing/screening. If these communication 
lines were not available, the research done would simply be useless since it would not be 
implemented in treating patients and treatment plans. Thus, effective communications and 
networks are the keys to making this vision a reality. In depth discussions must be had with 
purchasers, doctors and nurses, and others involved with cancer services within hospitals or 
the community across the region. 5 
The success of communications has been achieved by engaging the business, 
government, and scientific communities as partners in advocacy. 6 Once results are obtained 
and are ready to be made public, political action must be taken in order to implement the 
findings as soon as possible. By working together for legislative, regulatory, and funding 
changes, cancer advocates seek to achieve benefits, such as heightened screening, improved 
treatment, increased clinical trial enrollment, and rapid translation of research findings. 6  
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For example, the communications between the scientific world and the political world 
proved successful in the 80’s and 90’s when the Mammography Quality Standards Act was 
passed for expansion of the Breast and Cervical Cancer Early Detection Program, and there 
were extensive increases in federal funding for the National Cancer Institute. 6 The near 
constant updates of the scientific research must be told to the policy makers in order to 
immediately put the results into action. The policy makers can also decide where increased 
funding gets distributed to in order to be the most effective. As shown, these lines of 
communication have proved important and useful in the past, and will continue to be the key 
to early screening and detection.  
b. Costs 
Squamous cell carcinoma of the oral cavity and pharynx accounts for over 37,000 cases 
per year in the United States with about 8,000 deaths per year. 7Thus, it has become the sixth 
most common cancer in the world. This fact along with its late diagnosis, treating a case of 
this cancer can cost an upwards of $250,000. 8 Care and treatment for cancer has nearly 
doubled over the past twenty years, going from $96.1 billion in 1990 to $189.8 billion is 
2004.8 
As discussed earlier, the purpose of this research is to be able to detect whether a person 
is predisposed and/or at a higher risk of getting head and neck cancer. The National Cancer 
Institute (NCI) and others are now funding major initiatives to identify cancer at its earliest 
and most curable stage, for example, by basic research in identifying serum biomarkers 
indicating that an early cancer is developing. 9 Detecting cancer at such an early stage will 
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diminish the need for extremely expensive treatments. The cancer can and will be monitored 
closely by the patient’s doctor, and thus it will never fully develop since they will be able to 
properly care for it before it becomes life-threatening. As a large scale result, costs for cancer 
will decrease as fewer people need extensive treatment.   
By knowing what biomarkers are already present in a person’s blood, one may be more 
cautious of his/her actions since 75% of these cancers are related to alcohol and tobacco use. 
10
 People will also be more aware of the need for screening more often so that the tumors are 
caught at an early stage. Screening for oral, head and neck cancer can be easily completed in 
less than 5 minutes, and people should know the importance of this process, especially those 
who are predisposed to this form of cancer. 10   
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Chapter 4 
 
 
 
 
 
 
 
 
Improvements in Public Cancer Education 
 
 
 
a. Education/Advocacy 
 
“Knowledge is an important precursor to behavior change.”1 Education of cancer and the 
risks that can cause cancer is the first step to being able to cure cancer. Although scientists 
have made break-through discoveries about the risks that certain health choices have of 
getting cancer, those who are uneducated will not benefit. The importance of educating the 
public properly is key, and making sure that knowledge stays with them plays a crucial role.  
In 2005 alone, nearly 1.7 million Americans were diagnosed with cancer. Of those, 1,500 
would die per day. To make matters worse, it is estimated that 50%, if not more, of all cancer 
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would be preventable if individuals chose to live more healthy lifestyles.1 Such choices 
include diet, exercise, smoking tobacco, and drinking alcohol.   
The easiest way to inform the public about what they should know about modifiable 
cancer risks is by the media. “We should assume that cancer knowledge about topics 
receiving prominent coverage should be more easily retrieved from memory than those 
covered less frequently.”1 Health Information National Trends Survey (HINTS) conducted a 
survey of Americans asking if they reported paying attention to health information in the 
newspapers. Of 3,784 people surveyed, 51% and 58.8% recalled risks of food/diet and 
smoking, respectively. On the other hand, only 25%, 9% and 11% recalled information on 
exercise, avoiding sun/sunscreen, and alcohol, respectively.1  
Such results show which cancer risks are most closely watched by Americans - smoking. 
In the past, studies have shown that news coverage has been associated with decreases in the 
amount of people who smoke.1 The National Cancer Institute’s (NCI) Office of Cancer 
Communications ran the same study in two different years to analyze cancer news coverage. 
The first was done in 1977and the second in 1980. In both years, cancer news focused on 
cancer causes, celebrities with cancer, and treatment. The coverage on prevention went up 
from 1% in 1977 to 3% in 1980, and the discussion of risks went up from 20% to 50% as 
well. However, modifiable risk factors were rarely discussed in either year.1 
Among these modifiable cancer risks, smoking is the leading cause of preventable death 
in the United States. Smoking itself accounts for 30% of all cancer deaths.2 The health risks 
of smoking became public in 1964 with the first surgeon general’s report on smoking and 
health. A group of over 150 consultants and 7,000 scientific articles were examined over a 
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period of two years, resulting in the first public statement on the risks of smoking in relation 
to cancer. By 1970, labels were made for every pack of cigarettes warning people of the 
health risks.3 Since this breakthrough, America has become much more aware of the dangers 
of smoking. However, “research suggests that knowledge perceptions of associated risks of 
tobacco use may not be evenly distributed in the population.”2  
According to a study done by Health Information National Trends Survey (HINTS) in 
2003, the highest percentage of people who currently smoke was in the southeastern part of 
the United States and up into Wisconsin, Minnesota, and North Dakota. A corresponding 
study was done with the question, does smoking increase chances of cancer? The lowest 
percentage of people who believed the smoking made them at a higher risk for getting cancer 
were in nearly all the regions where smoking rates were highest. These graphs give some 
insight into where the media is failing to properly educate the public.2  
Another study was done in 2005 complimenting the previous results. The cancer 
mortality rates of each state were calculated and separated into categories: white males, black 
males, white females, and black females. Within the top ten states listed in each category as 
having the highest mortality rates for cancer, at least five of the states with the highest 
smoking rates from the previous study were listed. This information shows that not only is 
smoking increased where education and media is decreased, but the mortality rates are also 
increased.4 
The importance of educating the public on the risks that they can change themselves is 
extraordinarily important. Reducing one’s own risks allows him or her to take control of life. 
Being aware of what effects certain choices have on the body is the first step to making such 
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decisions. It has been proven that “low levels of scientific literacy generally impair the 
public’s ability to accurately understand and apply scientific concepts or issues to their own 
lives.”5 Thus, such concepts as modifiable preventions must be in the mainstream for the 
public to learn in order to change their lives. “Because what people learn is partly a function 
of available information, it is important to ascertain the extent to which the news media 
discuss cancer prevention.”4 
b. Legislation 
 
Legislation is what makes the dream of laboratory workers a possible reality. They are 
the ones who create the laws regarding cancer screening and coverage. These laws prove the 
necessity for screening as a direct result of the lab data. Thus, the current communication 
being implemented in terms of cancer research needs to be directed particularly toward 
legislation so that the laws can be made in the most efficient time.  
Coverage for cancer screening is not mandated in all states of the United States. A study 
was done in 2000 to “determine the prevalence and nature of state coverage mandates for 
cancer screenings.”6 In order to do so, researchers contacted the insurance departments of the 
50 US states, Washington DC, and Puerto Rico. They asked for copies of the state codes that 
mandated coverage for a variety of cancers by private insurers.6  
The results stated that “forty-three states and the District of Columbia currently mandate 
coverage of cancer screening. Breast cancer–screening coverage was most frequently 
mandated (n =44), followed by cervical (n =22), prostate (n =18), and colorectal cancer 
screening (n =1).Of 85 mandates in place, 57 have been passed since 1990. State mandates 
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for insurer coverage of cancer screening are common and increasing.”5 However, they are 
not mandatory in every state, and they do not cover every cancer.  
In an ideal situation, all states would have cancer screening coverage so that every person 
can get screened for all types of cancer. This would directly result in fewer extreme cases of 
cancer, and thus spending would decrease. The amount of people paying for extensive 
treatment would also decrease, and, as a long term result, the US would be saving money on 
treatment programs. The research done throughout this thesis shows why screening for head 
and neck cancer in particular should be mandatory. The amount of money that would be 
saved for both the patient and the state would be tremendous, as no extensive care would be 
necessary.  
In a long-term situation, it must be made mandatory that all patients are covered for early 
detection screening. This would ultimately lead to the cure for cancer. If every person had the 
ability to be screened for what is naturally in their body, along with the education necessary, 
they will be able to properly care for themselves and make wise decisions regarding their 
own health. Although these outcomes seem far off and quite costly as of now, the long-term 
savings would be huge, and cancer could slowly diminish.  
c. Aging Society 
 
The legislation that is current now makes it extremely difficult to decrease spending. In 
light of an aging society, the problem of treating cancer involves “rapid increase of US 
spending, greater use of screening services, and new treatments that come with a very high 
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price tag.”7  The present society is getting very used to new technology and relying on it 
completely. However, with this comes money, and that leads to an increase in spending. 
“Cancer is getting much more expensive to treat. One well-known reason is that most 
“breakthroughs” come with a very high price. Several recently approved chemotherapy 
agents for cancer come with price tags that are 300-500% higher than the costs of traditional 
treatments.”6 These statistics show how the aging society is hurting the possibility of curing 
cancer. The higher the price, the fewer people would realistically be able to afford such 
treatments. Therefore, the amount of people suffering from extreme, life-threatening cases of 
cancer would increase, and the amount being cured would decrease. 
This problem of an aging society directly portrays the need for education, advocacy, and 
proper legislation. Without these key factors, people will never be able to properly care for 
themselves because they will be uninformed, and they will also not be able to afford the new 
detection screening that will be made available. While it is true there will be a sudden 
increase in spending to provide all of this, the long-term money savings will be tremendous. 
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